059210 — Metabiomed Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Annual income statement for Metabiomed Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	R2020 December 31st	2021 December 31st	R2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	59,391	44,998	58,780	68,942	83,101
Cost of Revenue
Gross Profit	26,136	19,608	25,003	29,196	37,990
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	53,652	46,995	54,380	64,064	73,368
Operating Profit	5,739	-1,997	4,401	4,878	9,733
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	5,925	-3,616	7,584	2,910	7,805
Provision for Income Taxes
Net Income After Taxes	5,754	-3,087	9,521	2,846	10,027
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	3,346	-4,093	9,522	2,628	10,080
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	3,346	-4,093	9,522	2,628	10,080
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	238	-7.74	402	101	479
Dividends per Share